Litigation Details for HQ Specialty Pharma Corp. v. Fresenius Kabi USA, LLC (D. Del. 2021)
✉ Email this page to a colleague
HQ Specialty Pharma Corp. v. Fresenius Kabi USA, LLC (D. Del. 2021)
| Docket | ⤷ Sign Up | Date Filed | 2021-12-03 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Maryellen Noreika |
| Jury Demand | Defendant | Referred To | |
| Parties | FRESENIUS KABI USA, LLC | ||
| Patents | 10,130,646; 10,342,813 | ||
| Attorneys | William A. Rakoczy | ||
| Firms | Farnan LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in HQ Specialty Pharma Corp. v. Fresenius Kabi USA, LLC
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for HQ Specialty Pharma Corp. v. Fresenius Kabi USA, LLC (D. Del. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2024-08-30 | 261 | Jury Verdict | herein: Le The “’646 Patent” refers to U.S. Patent No. 10,130,646. This patent has also been referred…referred to as the “Asserted Patent” or the “Patent-in-Suit.” 2. “Plaintiffs” refers collectively to plaintiffs…evidence, that any of the following claims of the ’646 Patent is invalid for improper inventorship? YES NO (…evidence, that any of the following claims of the 646 Patent is invalid as obvious in light of the prior art…entitled to recover for infringement of the ’646 Patent? For any sales of Fresenius’ product for which | External link to document |
| 2021-12-03 | 3 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,130,646 B1 ;10,342,813 B2.… 3 December 2021 1:21-cv-01714 830 Patent Defendant District Court, D. Delaware | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
